Covid-19 vaccine market worth $10bn a year, analysts say

The future Covid-19 vaccine market could be worth more than $10bn a year, generating bumper revenues for pharmaceutical companies that have funded large parts of their research with government money. The calculations by analysts at Morgan Stanley and Credit Suisse assume that people will need to take a Covid-19 vaccine every year, like a flu jab, and are based on projected costs for the shot, currently hovering at about $20 a dose. “My base case assumption right now is that you will need annual vaccinations,” said Matthew Harrison, an analyst at Morgan Stanley. “[Covid-19] is not going to go away.” Even taking a “conservative approach” in which only those people who get a flu vaccine also take one for Covid-19, the market would be worth $10bn across developed countries, he said.